$CAMP News

CAMP4 to Participate in Upcoming Investor Conferences

Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Camp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

CAMP4 Moves Into Human Trials -- The Upside Is Underpriced

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

CAMP4 Therapeutics Receives Clearance From Australia’s TGA And Local HREC To Initiate Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic For SYNGAP1-Related Disorder

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones?

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

JP Morgan Upgrades Camp4 Therapeutics to Overweight, Raises Price Target to $9

Chardan Capital Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $6.5

Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

Camp4 Therapeutics Q1 EPS $(0.32) Misses $(0.29) Estimate, Sales $1.294M Beat $300.000K Estimate